When a child has to go viral to receive treatment, the system has already failed

When a child has to go viral to receive treatment, the system has already failed

Published on 4 June 2026 at 09:18 GMT

By Editorial Team SDG3

The story of Leo, a 12-year-old boy from Seville living with butterfly skin disease, has moved Spain. It has also revealed something profoundly uncomfortable about modern healthcare: sometimes, even in a wealthy European country, visibility can become the fastest route to treatment.

Leo lives with dystrophic epidermolysis bullosa, a rare genetic condition commonly known as butterfly skin disease because the skin can be as fragile as a butterfly’s wing. Minor friction can cause wounds and blisters. Daily care can be exhausting, painful and emotionally overwhelming for patients and families. The condition can also affect mucous membranes and, in severe cases, eating, movement and ordinary childhood activities.

In March 2026, the Junta de Andalucía announced that it would assume the cost of Vyjuvek, a pioneering gene therapy for Leo and other patients with butterfly skin disease in the region. The decision came after Leo’s case gained public attention, including his testimony in the European Parliament and appearances in the media. RTVE reported that the Andalusian government would seek a way to cover the treatment for Leo, while regional coverage described the decision as a milestone for patients who had been waiting for access.  

The news was rightly received with relief. No child should have to wait for a treatment that may improve wound healing, reduce pain and change daily life. Yet relief should not silence criticism. If a medicine becomes accessible only after a child’s suffering goes viral, then the system is not working as it should.

This is not a criticism of Leo, his family, the campaigners who supported him or the public figures who responded. Their effort was necessary because the system had left them with too few options. The criticism belongs elsewhere: with the slow, opaque and fragmented routes that often stand between regulatory approval and real access for patients with rare diseases.

Vyjuvek, whose active substance is beremagene geperpavec, is not an experimental rumour or a social media miracle. The European Medicines Agency recommended its authorisation for the treatment of wounds in patients with dystrophic epidermolysis bullosa, and the medicine received a marketing authorisation valid throughout the European Union on 23 April 2025.  

That distinction matters. In strict regulatory terms, the medicine is authorised in the European Union. Spain is part of that authorisation. But authorisation is not the same as access. A drug can be approved at European level and still remain out of reach for patients if national pricing, reimbursement and procurement processes have not been completed.

This is one of the great contradictions of European pharmaceutical policy. Europe can approve a medicine centrally, but patients do not access it centrally. After the European Medicines Agency assesses quality, safety and efficacy, and after the European Commission grants marketing authorisation, each Member State must still decide how the medicine will be priced, reimbursed and introduced into its health system. In Spain, that means further administrative steps involving national evaluation, pricing and funding decisions. The Ministry of Health explains that, after the national code is assigned by the Spanish medicines agency, the study of financing and price begins through the Directorate-General for the common portfolio of services of the National Health System and pharmacy.  

In theory, this protects the sustainability of public healthcare. It allows governments to assess therapeutic value, negotiate prices and decide how public money should be spent. That is legitimate. Public systems cannot simply accept any price set by a company, especially when innovative therapies can cost hundreds of thousands or even millions over time.

But in practice, these procedures can become a maze. Patients hear that a medicine is “approved in Europe”, then discover that approval does not mean availability. Families are told to wait for reports, negotiations, committees, codes, budgets and decisions. For common diseases, such delays are serious. For rare diseases, they can be devastating.

Butterfly skin disease exposes this problem sharply because the patient population is small, the condition is severe and the daily burden is visible. Cadena SER reported that Spain has around 500 people affected by butterfly skin disease, while DEBRA Piel de Mariposa has campaigned for national financing of Vyjuvek and delivered 150,000 signatures to the Ministry of Health.  

The ethical question is simple: should access to a life-changing rare disease treatment depend on whether a family can build a campaign powerful enough to break through political indifference?

The answer must be no.

Healthcare cannot become a competition in emotional visibility. A child who appears on television should not have a better chance of treatment than a child whose parents are exhausted, private, poor, disconnected or unable to campaign. A photograph with a president should not function as an unofficial access pathway. Social media should not have to do the work of health policy.

The Andalusian decision may help Leo and other patients in the region, and that is important. But it also risks creating a dangerous precedent if it remains an exception rather than a trigger for reform. Spain cannot rely on regional improvisation every time a new rare disease treatment emerges. Nor can it allow access to depend on postcode, political timing or media pressure.

The problem is not only Spanish. Across Europe, rare disease medicines often face a double bottleneck. First, they must pass the scientific and regulatory standards of the European system. Then they must survive national price and reimbursement negotiations, where high costs, limited clinical data, small patient numbers and budget impact create delays. Advanced therapies, including gene therapies, make this even more complex because they may be administered differently, require specialist centres and raise difficult questions about long-term value.

Vyjuvek is a clear example of this new era. It is a topical gene therapy designed to address the genetic cause of dystrophic epidermolysis bullosa by delivering functional copies of the COL7A1 gene to wounds. The company behind the product has described it as the first corrective medicine approved in Europe for dystrophic epidermolysis bullosa.  

That scientific progress should be celebrated. But innovation that exists on paper while patients wait in pain is an incomplete victory.

Spain needs faster, clearer and fairer mechanisms for medicines for rare and severe conditions. That does not mean eliminating evaluation or accepting unsustainable prices. It means building access pathways that recognise urgency, uncertainty and small patient populations. Conditional reimbursement, outcome-based agreements, early access mechanisms, transparent timelines and national coordination could reduce the gap between European authorisation and real treatment.

The current model too often asks families to endure uncertainty while institutions negotiate in slow motion. It also places patient organisations in an impossible position: they must support families, raise awareness, lobby administrations, explain scientific developments and, increasingly, fight for access medicine by medicine.

That is why organisations such as DEBRA matter so much. DEBRA International and DEBRA Piel de Mariposa in Spain support people living with epidermolysis bullosa, provide information, advocate for research and campaign for fair access to treatment. Their work has helped ensure that butterfly skin disease is not treated as an invisible condition affecting a small number of forgotten patients.

But civil society should not have to compensate for administrative failure. Patient organisations can inform, support and advocate. They should not have to drag a health system into action through viral campaigns.

Leo’s case should therefore be remembered in two ways. First, as a story of courage: a child and his family helped make visible a disease that too many people did not understand. Second, as a warning: when justice arrives only after public exposure, it has arrived too late and too unevenly.

The lesson is not that every patient should become a campaign. The lesson is that no patient should have to.

A serious healthcare system must be able to respond before a case becomes a headline. It must recognise that rare does not mean optional, that bureaucracy should serve patients rather than exhaust them, and that European approval must be followed by real, predictable and equitable access.

Butterfly skin disease is cruel enough. The path to treatment should not make it crueller.

More information: https://pieldemariposa.es/en/